Q-omics provides the consensus-scored CHCHD1 profile across patient tissues and cancer cell-line models. CHCHD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CHCHD1 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, CHCHD1 RNA expression shows 19,161 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LIHC, and THYM as cancer lineages where CHCHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD1 survival associations across molecular data types. CHCHD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD1 RNA expression–survival associations across cancer types. High CHCHD1 expression shows unfavorable associations in UVM, ACC, HNSC, LIHC and LUAD, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CHCHD1 RNA expression.
This table summarizes CHCHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHCHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD1 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, STAD, UCEC and BRCA. The LIHC box plot shows higher CHCHD1 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with CHCHD1 in patient tissues and cancer cell lines. In patient samples, CHCHD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHCHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
